Cardiovascular disease in the developing world and its cost-effective management

被引：282
作者：
Gaziano, TA
机构：
[1] Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Cardiol, Boston, MA 02120 USA
[2] Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Social Med, Boston, MA 02120 USA
来源：
CIRCULATION | 2005年 / 112卷 / 23期
关键词：
cost-benefit analysis; epidemiology; heart failure; myocardial infarction; prevention;
D O I：
10.1161/CIRCULATIONAHA.105.591792
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页码：3547 / 3553
页数：7
相关论文
共 23 条
  • [1] *AM HEART ASS, 2003, HEART DIS STROK STAT
  • [2] [Anonymous], CARDIOVASCULAR DIS D
  • [3] [Anonymous], 2002, World Development Indicators
  • [4] [Anonymous], 2001, MACROECONOMICS HLTH
  • [5] [Anonymous], 2003, WORLD HLTH REPORT 20
  • [6] *DCPP SECR, 2004, DIS CONTR PRIOR PROJ
  • [7] GAZIANO T, IN PRESS CARDIOVASCU
  • [8] COST-EFFECTIVENESS OF HMG-COA REDUCTASE INHIBITION FOR PRIMARY AND SECONDARY PREVENTION OF CORONARY HEART-DISEASE
    GOLDMAN, L
    WEINSTEIN, MC
    GOLDMAN, PA
    WILLIAMS, LW
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1991, 265 (09): : 1145 - 1151
  • [9] Medical care expenditures for hypertension, its complications, and its comorbidities
    Hodgson, TA
    Cai, LM
    [J]. MEDICAL CARE, 2001, 39 (06) : 599 - 615
  • [10] Leeder SR., 2004, RACE TIME CHALLENGE
123